




## Supplementary data



**Figure S1.** Doxorubicin-induced toxicity in hiPSC-differentiated cardiomyocytes (iPSC-CMs), and H9c2 and Huh7 cells. (a) IC<sub>50</sub> of doxorubicin treatment in iPSC-CMs, H9c2, and Huh7 cell after 72 h. (b) Effect of doxorubicin dose on cell viability after treatment for 72 h. (c) Effect of doxorubicin treatment duration on cell viability. Each data point represents the mean  $\pm$  SEM ( $n = 3$ ).



**Figure S2.** Contractile dysfunction in doxorubicin-treated hiPSC-differentiated cardiomyocytes (iPSC-CMs). (a-c) Effect of doxorubicin dose (0, 2, 4, 8, and 12 μM) on muscle motion of iPSC-CMs and H9c2 cells after treatment for 24 h. (d-f) Effect of time on muscle motion of iPSC-CMs and H9c2 cells treated with 0.5 μM of doxorubicin for 72 h. (d) Contraction amplitude, (e) contraction velocity, and (f) relaxation velocity. Each data point represents the mean  $\pm$  SEM ( $n = 3$ ).



**Figure S3.** Quantification of reactive oxygen species (ROS) generated in doxorubicin-treated human induced pluripotent stem cell-derived cardiomyocytes. \*\*\* Significantly different from vehicle ( $p < 0.001$ ).